TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

NCT00255099 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

593

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV

Interventions

DRUG: TMC125
DRUG: Placebo

Sponsor

Tibotec Pharmaceuticals, Ireland